Tagged Articles

Xarelto 217 articles

Xarelto side effects victims appeal to Fifth Circuit

Two men who lost bellwether trials blaming the blood thinner Xarelto for uncontrolled bleeding events told a Louisiana federal court that they are appealing some orders and the final judgments to the Fifth Circuit. Plaintiffs Jospeh Boudreaux and Joseph Orr, both of whom had sued Xarelto makers Johnson & Johnson’s Janssen Pharmaceuticals and Bayer, filed notices of appeal on a collective nine court decisions, including requests for new trials. Both plaintiffs are appealing an April 13 order in which Judge Eldon E. Fallon rejected their attempts to stop speculative testimony and opinions by the drug companies’ expert. A total of ... Read More

Nixed Xarelto case highlights importance of early filing

A Louisiana federal judge kicked Herbert Louiviere’s failure-to-warn case out of a massive multi district litigation against the makers of the blood thinner Xarelto, saying he waited too long to file a lawsuit alleging the drug caused his internal bleeding. The ruling highlights the importance of not delaying to file a lawsuit. Louiviere was prescribed Xarelto in January 2013. The drug is used to prevent strokes in people with the common heart rhythm abnormality atrial fibrillation, as well as to prevent and treat some blood clot conditions. On March 6, 2013, Louiviere was hospitalized for a gastrointestinal bleed, at which ... Read More

More major bleeding with Xarelto than aspirin

When Bayer announced it was pulling the plug on a late-stage clinical trial that showed its blood thinner Xarelto was no better than low-dose aspirin at preventing strokes and blood clots in patients who have had a recent stroke, the company also revealed that the blood thinner caused more major bleeding events than aspirin. The bleeding rates were relatively low overall, which normally may have gone under the radar if Bayer and Johnson & Johnson’s Janssen Pharmaceuticals were not facing nearly 20,000 lawsuits over Xarelto bleeding risks. Xarelto used to be the top selling novel oral anticoagulant (NOAC) on the ... Read More

Risperdal, Xarelto mass tort programs largest in PA court

Two of the biggest mass tort programs on the Philadelphia Complex Litigation Center docket involve medications that are all or partially made by Johnson & Johnson and its subsidiary Janssen Pharmaceuticals – the antipsychotic Risperdal and the blood thinner Xarelto. Risperdal is used to treat schizophrenia, bipolar disorder and irritability with autism in adults and children. It is often used off-label to treat behavioral problems including attention deficit hyperactivity disorder (ADHD) and Tourette’s. The drug has been found to raise levels of prolactin, the hormone produced by pregnant women to induce lactation. When this occurs in adolescent boys taking Risperdal, ... Read More

Motions considered before Xarelto side effects trial

Philadelphia Court of Common Pleas Judge Arnold New is considering a several motions in next month’s Xarelto side effects bellwether trial, in particular whether the court should allow punitive damages. Plaintiff Lynn Hartman is suing Xarelto makers Johnson & Johnson’s Janssen Pharmaceuticals and Germany-based Bayer for not adequately warning that use of the drug could cause major bleeding, including gastrointestinal bleeds and brain hemorrhages. The drug companies claim that either New Jersey or German law should apply to the case, which would mean Hartman would not be able to seek punitive damages. Hartman’s attorneys argue that Indiana law applies in ... Read More

Xarelto clinical trial halted early for lack of efficacy

A clinical trial pitting the blood thinner Xarelto against low-dose aspirin in patients who had recently suffered a stroke was stopped prematurely for lack of efficacy, Bayer announced. Patients taking Xarelto also had more major bleeding events, the study revealed. Xarelto makers Bayer and Johnson & Johnson’s Janssen Pharmaceuticals had high hopes that the study would show Xarelto superior in efficacy, even boasting that they expected the product’s sales to jump from $3.4 billion annually to more than $5.3 billion a year. Bleeding risks are a known side effect with Xarelto. The drug companies currently face more than 18,000 lawsuits in state and ... Read More

Some drugs increase bleeding risk in patients taking Xarelto

Novel oral anticoagulants (NOCA), like the blood thinner Xarelto, can interact with other medications and increase the risk for major bleeding events compared to NOCAs alone, according to new research. NOCAs first hit the market in 2010, and are being prescribed more often to prevent strokes in patients with the common heart rhythm abnormality called atrial fibrillation. They are also used to treat or prevent deep vein thrombosis and pulmonary embolism and prevent blood clots in patients who have recently undergone hip or knee replacement therapy. “However, for patients with atrial fibrillation, NOACs still pose a major bleeding risk, which ... Read More

Xarelto victim wants new trial over injuries

Attorneys for a woman who sued Janssen Pharmaceuticals and Bayer over bleeding injuries allegedly caused by the blood thinner Xarelto have filed a motion seeking a retrial based on new evidence that contradicts courtroom testimony that could have swayed jurors. A jury from the U.S. District Court for the Southern District of Mississippi found in favor of the drug companies during the third bellwether trial over Xarelto side effect. Dora Mingo, 69, claimed that she was prescribed Xarelto after suffering a blood clot following hip replacement surgery. But shortly after starting treatment with the blood thinner, she suffered a life threatening ... Read More

New evidence could lead to Xarelto re-trial

Attorneys for a woman who suffered a major bleeding event after taking the blood thinner Xarelto are seeking a new trial after discovering new evidence that questions the accuracy of statements made by the drug’s makers. Jurors found in favor of Johnson & Johnson’s Janssen Pharmaceuticals and Bayer. During the trial, jurors were told by the drug companies that there was no effective test to determine whether patients were at an increased risk for internal bleeds while taking Xarelto, and dismissed plaintiff Dora Mingo’s expert witness’ testimony that a lab test called prothrombin time – or PT – would not ... Read More

Korea adds severe skin reaction warning to Xarelto

Korea’s Ministry of Food and Drug Safety (MFDS) is requiring an update to the safety label of the blood thinner Xarelto to include new warnings regarding the risk of the serious and sometimes fatal skin reactions known as Stevens Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). The warning comes after the European Commission issued a public safety alert regarding serious skin conditions with Xarelto. Most side effects were reported within the first week of treatment. The ministry collected opinions and reviewed them last month and determined that the warnings should also come with a recommendation for doctors to discontinue ... Read More